Both ATM and RAD51B are important genes in the homologous recombination (HR) repair pathway, and their targeted drug olaparib has been approved by the US Food and Drug Administration (FDA) for metastatic castration-resistant prostate cancer [18], suggesting that cervical cancer patients may also benefit from PARP inhibitors, which is consistent with the enrichment results of the above germline oncogenic mutated genes. This evidence concerns the gene ATM and prostate carcinoma.